The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery

被引:2
|
作者
Castaneda, Javier [1 ]
de Galan, Bastiaan E. [2 ,3 ,4 ]
van Kuijk, Sander M. J. [5 ]
Arrieta, Arcelia [1 ]
van den Heuvel, Tim [1 ]
Cohen, Ohad [1 ]
机构
[1] Medtron Int Trading Sarl, Route Molliau 31, CH-1131 Tolochenaz, Switzerland
[2] Maastricht Univ Med Ctr, Dept Internal Med, Maastricht, Netherlands
[3] Maastricht Univ, CARIM Sch Cardiovasc Dis, Maastricht, Netherlands
[4] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands
[5] Maastricht Univ Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
来源
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 12期
关键词
glycaemic control; hypoglycaemia; mean glucose; real-world evidence; time in tight glucose range; REAL-WORLD USERS; SYSTEM; RANGE; TIME;
D O I
10.1111/dom.15955
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The aim was to determine the interdependence of targets for glucose management indicator (GMI), time within the ranges of 70-180 mg/dL (TIR) and 70-140 mg/ dL (time in tight glucose range [TITR]), time above 180 mg/dL (TA180) and 250 mg/ dL (TA250) and time below 70 mg/dL (TB70) and 54 mg/dL (TB54) and its implications for setting targets in automated insulin delivery (AID). Materials and Methods: Real-world data from individuals with type 1 diabetes using the 780G system were used to calculate the receiver operating characteristic curves and establish interdependent targets for time in ranges based on several GMI benchmarks. Correlation, regression and principal component analysis were used to determine their association and dimensionality. Results: In individuals aged >15 years (n n = 41 692), a GMI <6.5% required targets of >81%, >58%, <15% and <1.9% for TIR, TITR, TA180 and TA250, respectively, with high sensitivity, specificity and accuracy (>90%), whereas these values were poor for time in hypoglycaemia and GMI, which had a modest correlation (-0.21 to-0.43). Two dimensions emerged: (1) GMI, TIR, TITR, TA180 and TA250, and (2) TB70 and TB54, explaining 95% of total variability. GMI (or TIR) and TB70 explained >81% of the variability in the remaining continuous glucose monitoring (CGM) metrics, providing accurate predictions. Individuals aged <= 15 years (n n = 14 459) showed similar results. Conclusion: We developed a methodology to establish interdependent CGM targets for therapies with CGM data outputs. In AID with the 780G system, a GMI <7% requires time in ranges close to consensus targets. Targets for GMI, TIR, TITR, TA180 and TA250 could be reduced to targets for GMI or TIR, whereas targets for time in hypoglycaemia are not inherently tied to GMI/TIR targets.
引用
收藏
页码:5836 / 5844
页数:9
相关论文
共 50 条
  • [31] Perinatal outcomes and time-in-range on continuous glucose monitoring for type 1 diabetes
    Sobhani, Nasim C.
    Goemans, Sophie L.
    Nguyen, Antoinette
    Richley, Michael
    Gabby, Lauryn
    Han, Christina S.
    Ramos, Gladys A.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2023, 228 (01) : S72 - S73
  • [32] Automated Insulin Delivery in Pregnancies Complicated by Type 1 Diabetes
    Benhalima, Katrien
    Polsky, Sarit
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2025,
  • [33] Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes
    Karakus, Kagan E.
    Shah, Viral N.
    Klonoff, David
    Akturk, Halis K.
    DIABETES OBESITY & METABOLISM, 2023, 25 (11): : 3144 - 3151
  • [34] Recently diagnosed with type 1 diabetes: glycaemic outcomes with the Omnipod® Automated Insulin Delivery System
    Forlenza, G. P.
    DeSalvo, D. J.
    Bode, B. W.
    Criego, A. B.
    Brown, S. A.
    Schoelwer, M. J.
    Mehta, S. N.
    Laffel, L. M.
    MacLeish, S. A.
    Huyett, L. M.
    Boyd, J.
    Gurlin, R. E.
    Ly, T. T.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S345 - S345
  • [35] NEXT GENERATION AUTOMATED INSULIN DELIVERY: ON-BODY ECOSYSTEM FOR AUTOMATED INSULIN DELIVERY IN TYPE 1 DIABETES
    Dassau, E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A1 - A2
  • [36] Less glucose variability with insulin detemir compared to NPH insulin in subjects with type 1 diabetes undergoing continuous glucose monitoring
    Jones, David R.
    Clauson, Per
    Ong, Stephanie
    Mathieu, Chantal
    DIABETES, 2006, 55 : A118 - A118
  • [37] Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes
    McQueen R.B.
    Ellis S.L.
    Campbell J.D.
    Nair K.V.
    Sullivan P.W.
    Cost Effectiveness and Resource Allocation, 9 (1)
  • [38] Continuous glucose monitoring and insulin pump therapy in pregnant women with type 1 diabetes mellitus
    Lason, Izabela
    Cyganek, Katarzyna
    Witek, Przemyslaw
    Matejko, Bartlomiej
    Malecki, Maciej T.
    Skupien, Jan
    GINEKOLOGIA POLSKA, 2021, 92 (10) : 675 - 681
  • [39] Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy
    Heptulla, RA
    Allen, HF
    Gross, TM
    Reiter, EO
    PEDIATRIC DIABETES, 2004, 5 (01) : 10 - 15
  • [40] Clinical Utilities of Continuous Glucose Monitoring and Insulin Pumps in Pediatric Patients with Type 1 Diabetes
    Lee, Jieun
    Kim, Jae Hyun
    EWHA MEDICAL JOURNAL, 2021, 44 (03): : 55 - 62